Navigation Links
Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
Date:10/27/2010

BURLINGTON, Mass., Oct. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, the combined sales of seven new therapies for the treatment of breast cancer will total nearly $5 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Among the emerging therapies for the indication, surveyed experts are particularly enthusiastic about agents in the Poly ADP-Ribose Polymerase (PARP) inhibitor drug class.  

The Pharmacor 2010 findings from the topic entitled Breast Cancer reveal that Sanofi-Aventis's PARP inhibitor iniparib has the potential to achieve blockbuster peak-year sales in excess of $1 billion. In addition to iniparib, other key PARP inhibitors in development include AstraZeneca's olaparib and Abbott Laboratories' veliparib. Sales of agents targeting HER2-positive breast cancer will increase by almost $2 billion through 2019. This growth will be fueled by the increased uptake of Roche/Chugai's Herceptin, GlaxoSmithKline's Tykerb/Tyverb and the approval of three new HER2-targeted therapies -- Roche/Genentech/Chugai's trastuzumab-DM1, Roche/Chugai's Omnitarg and Pfizer's neratinib.

The Pharmacor 2010 findings also reveal that Roche/Genentech/Chugai's Avastin has garnered substantial patient share, particularly in the metastatic triple-negative and metastatic HR-refractory treatment settings, where effective therapies are few. However, in July 2010, Avastin's future in this indication was cast in doubt after the Oncologic Drugs Advisory Commission recommended that the FDA rescind the agent's conditional approval for first-line metastatic HER2-negative breast cancer. Additionally, Avastin's European label for breast cancer is also under review by the European Medicines Agency.

"The fact that the National Comprehensive Cancer Network guidelines panel for breast cancer recently affirmed its existing recommendation for Avastin is a positive sign for Roche. However, even in the event that Avastin manages to hang on to a first-line metastatic breast cancer label it's sales -- which surpassed $1 billion for breast cancer alone in 2009 in the world's major markets -- will plummet over the next several years," said Decision Resources Analyst Niamh Murphy, Ph.D. "By 2019, sales of Avastin in breast cancer will drop to $350 million as a result of oncologists' diminishing confidence in the agent, increased prescribing and reimbursement restrictions and competition from emerging therapies -- most notably, iniparib and Eli Lilly's VEGF inhibitor, ramucirumab."

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity
2. FDA Issues Complete Response Letter For Trabectedin Combined With DOXIL
3. Nanoelectronic transistor combined with biological machine could lead to better electronics
4. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
5. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
6. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
7. Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 -
8. Microbix Has Best-Ever Quarterly Sales
9. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
10. Immune Biosimilars Will Erode $10.8 Billion in Immune Biologics Brand Sales in 2019 Across the U.S., EU5 and Japan
11. Dynamic Ventures Corporation enters into a long-term agreement that brings $50 million annual sales opportunity for wholly owned subsidiary EZ-Build.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , ... May 27, 2016 , ... Weeks after hosting ... in Phoenix, Dr. Michael Fitzmaurice, hand surgeon and founder of the Fitzmaurice Hand Institute, ... The Wrist MRI machine is a state-of-the-art technology and only 1 of about 3 ...
(Date:5/27/2016)... At present, the Biotech sphere is in a ... volatility is what makes this industry interesting to consider. Here ... (NASDAQ: SNTA ), CTI BioPharma Corp. (NASDAQ: ... and Heat Biologics Inc. (NASDAQ: HTBX ). Sign ... these stocks at: http://www.activewallst.com/register/ ...
(Date:5/26/2016)... Despite the volatility that continues to envelop the ... research on ActiveWallSt.com directs the investor community,s focus on the ... ), Cerus Corp. (NASDAQ: CERS ), Arrowhead Pharmaceuticals ... Inc. (NASDAQ: FPRX ). Register with us today ... On Wednesday, shares in Massachusetts ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lajollacooks4u has become a rising hotspot ... rated one of its top attractions. Fortune 500 companies, such as Illumina, Hewlett-Packard, ... unique and intimate team-building experience. , Each event kicks off with an olive oil ...
Breaking Biology Technology:
(Date:3/15/2016)... New York , March 15, 2016 ... new market report published by Transparency Market Research "Digital Door ... Trends and Forecast 2015 - 2023," the global digital door ... US$ 731.9 Mn in 2014 and is forecast to grow ... 2023. Growth of micro, small and medium enterprises (MSMEs) across ...
(Date:3/11/2016)... , March 11, 2016 ... market research report "Image Recognition Market by Technology (Pattern ... and Advertising), by Deployment Type (On-Premises and Cloud), by ... 2022", published by MarketsandMarkets, the global market is expected ... USD 29.98 Billion by 2020, at a CAGR of ...
(Date:3/9/2016)... Fla. , March 9, 2016  Crossmatch ... authentication and enrollment solutions, today announced the addition ... ® Altus multi-factor authentication platform. New ... InfoSec managers to step-up security where it,s needed ... Washington, DC . --> ...
Breaking Biology News(10 mins):